Modelling of Cardiac β-adrenoceptor desensitisation to understand heart failure therapy Karin Lundengård, CMIV Jordi Altimiras, IFM.

Slides:



Advertisements
Similar presentations
Ionotropic Therapy in Acute Heart Failure
Advertisements

Exercise Stress Electrocardiography
Cardiac Drugs in Heart Failure Patients Zoulikha Zair 28 th May 2013 N.B. some drugs overlap with treatment of hypertension….bonus revision wise!!!!
Sympathetic Drugs. Stress and The Adrenal Glands.
Multi-level Modeling of Type 2 Diabetes Elin Nyman Diabetes and Integrative Systems Biology Clinical and Experimental Medicine Linköping University Workshop.
B) Drug Therapy (Antihypertensives) ACEi B.B CCB D iuretics. Centrally acting agents: alphametyldopa, HTN + pregnancy.
Pharmacology II The Autonomic Nervous System Adrenergic antagonists
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 9 th Lecture.
Heart Remember or cardiac memory.  Background Can heart remember?
MODULE 3 CHAPTER 2C HYPERTENSION AND COPD.
Clinical Toxicology & Pharmacology, Newcastle Mater Misericordiae Hospital Calcium channel blockers Professor Ian Whyte Hunter Area Toxicology Service.
Small Platform Catheter-Based Left Ventricular Assist Device Support Suppresses Cardioprotective Beta Arrestin- Mediated Signal Transduction Keshava Rajagopal,
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Beta-Adrenergic Blockers  Types of adrenoceptors Alpha-1  Vasoconstriction  Increased peripheral resistance  Increased blood pressure Alpha-2  Inhibition.
1 National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004 CIHR Team Grant.
Heart control DR. HANA OMER.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
Drugs for Hypertension
CARDIOVASCULAR DISEASE 1.HYPERTENSION 2.ISCHAEMIC HEART DISEASE 3.THROMBO-EMBOLIC DISEASE Myocardial infarction Stroke Medical Pharmacolgy & Therapeutics.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Heart Failure (HF) : Overview Common underlying heart diseases or causes of HF 1.Valvular HD-Rheumatic etiology 2.Cardiomyopathy – Dilated type 3.Ischemic.
Multi-Scale Modeling Incorporating Insulin Signaling in Adipocytes and Whole-body Glucose Homeostasis Elin Nyman Diabetes and Integrative Systems Biology.
Drugs for Congestive Heart Failure
THE PHARMACOLOGY OF ADRENERGIC RECEPTORS M.T. Piascik PHA 824 December 11 & 16, 2008.
1 Drug Treatment of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
Infantile Hemangioma: Natural History & Treatment - Involution phase: 50% of infantile hemangiomas show complete involution by age 5 years & 70% by age.
Beta Blockers.
1 Drug Therapy of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
PROF. AZZA El-Medany Department of Pharmacology OBJECTIVES At the end of lectures the students should Describe the different classes of drugs used for.
Acute Myocardial Infarction Joseph D. Lynch, MD. Acute Myocardial Infarction Mechanism Clinical Presentation Diagnosis Management.
Pharmacology of Heart failure
Nursing and heart failure
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
A Critical Analysis of the Clinical Use of Incretin-Based Therapies The benefits by far outweigh the potential risks Featured Article: Diabetes Care Volume.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
VST 206 outline notes. Membrane permeability stimuli Biochemicals mechanical impulses physical factors.
 Introduction  Classification of inotropes  Postoperative myocardial dysfunction.  Choice of inotrope  Indications in specific settings.
Drugs used for Congestive Heart Failure
23 كانون الثاني، كانون الثاني، كانون الثاني، كانون الثاني، كانون الثاني، 1623 كانون الثاني، كانون الثاني، كانون الثاني،
Internal Medicine Workshop Series Laos September /October 2009
1 Shock. 2 Shock refers to an abnormality of the circulatory system in which there is inadequate tissue perfusion due to a relatively or absolutely inadequate.
GRK2 Inhibition Reduces Post-Myocardial Infarction Cardiac Fibroblast-Mediated Adverse Remodeling Jennifer L. Philip 1, Xianyao Xu 1,Mei Han 1, Jinju Li.
PHARMACOLOGY OF ANS part 3 General Pharmacology M212
Pharmacology PHL 101 Abdelkader Ashour, Ph.D. 10 th Lecture.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
PRESSORS & ANTIHYPERTENSIVES Luis R. Sauceda-Cerda, MD PGY-4.
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
MODULATABLE (STIMULATION) FUNCTION SECONDARY DAMAGE SUPPORT ACTIVATION OF COMPENSATORY MECHANISMS* ● Adrenergic ● RAAS ● Other INTRINSIC (RESTING) FUNCTION.
Donna H. Korzick, Ph.D. Noll Physiological Research Center and The Department of Kinesiology Regulation of Cardiac EC-Coupling: A Cellular Update Experimental.
BLOOD PRESSURE REGULATION:
β-adrenergic antagonists
Cardiac excitation-contraction coupling and its regulation by positive inotropic drugs. The cardiac cycle is initiated by membrane depolarization, which.
Drugs for Hypertension
Positive inotropes improve cardiac function by a number of mechanisms, which usually result in increased intracellular calcium. Xenobiotics that [1] increase.
Cyclic nucleotide signalling in cardiac myocytes and its relation to contraction and arrhythmias. Cyclic nucleotide signalling in cardiac myocytes and.
No conflict of interest
Adrenergic agonists.
Nat. Rev. Cardiol. doi: /nrcardio
Beta-adrenergic blocking agents
Left ventricular dysfunction after degenerative mitral valve repair: A question of better molecular targets or better surgical timing?  Jordan D. Miller,
Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes  B.M. Biccard, J.W. Sear, P. Foëx 
Chapter 17: Function of the Heart
Recent advances – levosimendan
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.
Presentation transcript:

Modelling of Cardiac β-adrenoceptor desensitisation to understand heart failure therapy Karin Lundengård, CMIV Jordi Altimiras, IFM

2 Outline Project and groups β AR in the heart and heart failure therapy Modeling methodology The models Future prospects

3 Altimiras' group at IFM Phenotypic plasticity of cardiovascular function during fetal development: mechanisms and consequences Research Interests:

4 Project collaboration  Collaboration with Gunnar Cedersund, IKE/IMT and Elin Nyman, IKE  LCSB

5 Outline Project and groups β AR in the heart and heart failure therapy Modeling methodology The models Future prospects

6 β-adrenoceptors in the heart Catecholamines are key stimulators of cardiac function (positive chronotropic and inotropic effects) by binding to  -adrenoceptors Loss of βAR sensitivity to adrenergic agonists occurs in heart failure

7 Cardiac function Release of catecholamines Chronic β-AR stimulation Receptor desensitisation Cardiac function HEART FAILURE!

8 Baspresentation LiU Heart failure therapy Based on ACE inhibitors and β-blockers β-blockade substantially improves pump function in the long term

9 « An entire explanation for improved cardiac function in patients using β-blockers is unknown… » « … and, in fact may be quite complicated, considering the numerous intracellular signaling pathways associated with β- adrenergic receptors » Tilley and Rockman. Expert Rev.Cardiovasc.Ther. 4:417 (2006) Aims of our work Collect experimental data on βAR desensitization Construct and optimize a βAR signaling model

10 Outline Project and groups β AR in the heart and heart failure therapy Modeling methodology The models Future prospects

11 Modelling Methodology Mechanistic model, ODEs Time series data Iteratively with experiments HypothesisModel Optimization Experiments

12 Outline Project and groups β AR in the heart and heart failure therapy Modeling methodology The models Future prospects

13 d(B1)/dt = k1d*B1int + k1c*B1p - kbas1*B1 - B1*(kiso+kip1)*H1 d(B1act)/dt = kbas1*B1 + B1*(kiso+kip1)*H1 - k1a*B1act*(kGRK*GRKact+PKAact) d(B1p)/dt = k1a*B1act*(kGRK*GRKact+PKAact) - (k1b+k1c)*B1p d(B1int)/dt = k1b*B1p – k1d*B1int d(B2)/dt = k2d*B2int + k2c*B2p - kbas2*B2 - B2*(kiso+kip2+kter)*H2 d(B2act)/dt = kbas2*B2 + B2*(kiso+kip2+kter)*H2 - k2a*B2act*(kGRK*GRKact+PKAact) d(B2p)/dt = k2a*B2act*(kGRK*GRKact+PKAact) - (k2b+k2c)*B2p d(B2int)/dt = k2b*B2p - k2d*B2int d(Gs)/dt = k3b*Gsact - k3a*Gs*(B1act+B2act) d(Gsact)/dt = k3a*Gs*(B1act+B2act) - k3b*Gsact d(Gi)/dt = k3d*Giact - k3c*B2p*Gi d(Giact)/dt = k3c*B2p*Gi - k3d*Giact d(AC)/dt = k4b*ACact - k4a*Gsact/(kinh+Giact)*AC d(ACact)/dt = k4a*Gsact/(kinh+Giact)*AC - k4b*ACact d(cAMP)/dt = cAMP0 + ACact*k5 – kPKA*PKAact*cAMP d(GRK)/dt = - cAMP*k6a*GRK + k6b*GRKact d(GRKact)/dt = cAMP*k6a*GRK - k6b*GRKact d(PKA)/dt = - cAMP*k6c*PKA + k6d*PKAact d(PKAact)/dt = cAMP*k6c*PKA - k6d*PKAact

14

15

16

17

18

19

20

21

22

23

24

25

26 1 2

27

28

29 1 2

30

31

32 Theoretical data Return of signal Experimental data Predict resting time Original model Minimal models All smaller models

33 Outline Project and groups β AR in the heart and heart failure therapy Modeling methodology The models Future prospects

34 Future prospects Study β-AR desensitization and beta-blocker effects in the murine myocardial infarction model in collaboration with Prof. de Muinck, Clinical Physiology Further development of the model to account for the effects of beta- blockade Why don’t fetal βARs desensitize?

Thank you for your attention! Questions?